Efficacy of 150 mg clopidogrel and triple antiplatelet in patients with acute anterior myocardial infarction undergoing PCI
- VernacularTitle:氯吡格雷150 mg与三联抗血小板对急性前壁心肌梗死PCI患者的疗效比较
- Author:
Cong WANG
;
Xiaobo ZHOU
;
Shuangqing KOU
- Publication Type:Journal Article
- Keywords:
cilostazol;
acute anterior myocardial infarction;
triple antiplatelet;
late lumen loss;
target lesion revascularization
- From:
Chinese Journal of Biochemical Pharmaceutics
2015;37(7):73-75
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the efficacy and safety of 150 mg clopidogrel and triple antiplatelet in acute anterior myocardial infarction ( AMI) patients undergoing percutaneous coronary intervention ( PCI).Methods Totally 50 patients who had been diagnosed as acute anterior myocardial infarction and prepared to PCI treatment were randomly divided into two groups:150 mg clopidogrel group ( asprin 100 mg/d qd+clopidogrel 150 mg/d qd) and triple antiplatelet group ( cilostazol 100 mg bid+asprin 100 mg/d qd+clopidogrel 75 mg/d qd).The coronary lession through CAG, incidence of major cardiovascular events and safety in 6 months were observed and assessed.ResuIts There was no significant difference in level of target lesion diameter between two groups after PCI instantly (2.75 ±0.29 mm vs.2.69 ±0.31 mm).There were no significant differences of late lumen loss (LLL) and target lesion revascularization (TLR) between triple antiplatelet group and 150 mg clopidogrel group (0.22 ±0.46 mm vs.0.38 ±0.65 mm; 8%vs.24%) , but the two indexes were improved in a certain extent.There were no significant differences in hemorrhage and major adverse cardiovascular events ( MACE) between two groups.ConcIusion The triple antiplatelet therapy could reduce the late lumen loss and target lesion revascularization, and not increase hemorrhage and adverse cardiovascular events.
